Discuss This Drug

baricitinib

CHEBI:CHEBI_95341

Definition

A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis.

Chemical Information

Molecular Formula
C16H17N7O2S
Molecular Mass
371.420
Charge
0
SMILES
CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
InChI
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
InChIKey
XUZMWHLSFXCVMG-UHFFFAOYSA-N

Alternative Names

  • {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile
  • 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
  • 2-(3-(4-(3H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
  • baricitinib
  • baricitinibum
  • INCB 028050
  • INCB-028050
  • INCB028050
  • LY 3009104
  • LY-3009104
  • LY3009104
  • Olumiant

Treatment Applications

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

DRON_00010000
2047232
oboInOwl#hasDbXref
Wikipedia:Baricitinib
core#notation
CHEBI:95341

Additional References

Wikipedia:Baricitinib

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

has_treatment
http://purl.obolibrary.org/obo/DOID_0060386
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
2047232
generic_name
BARICITINIB
oboInOwl#hasDbXref
Wikipedia:Baricitinib
oboInOwl#id
CHEBI:95341
brand_name
Baricitinib
brand_name_base
Baricitinib
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
dosage_form
CRYSTAL
labeler_name
Chunghwa Chemical Synthesis & Biotech. Ltd
product_ndc
0110-4479
application_number
NDA207924
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_76617
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
core#notation
CHEBI:95341
rxcui
2601725
listing_expiration_date
20241231
route
ORAL
active_ingredient_strength
5 kg/5kg
marketing_start_date
20170116
package_marketing_start_date
10-JAN-19
manufacturer_name
Eli Lilly and Company
pharm_class_epc
Janus Kinase Inhibitor [EPC]
pharm_class
Janus Kinase Inhibitors [MoA]
pharm_class_moa
Janus Kinase Inhibitors [MoA]
spl_id
14a2ffe3-1d7e-4d1b-ac44-1698d5f92da4
active_ingredient_name
BARICITINIB
package_ndc
0110-4479-71
package_description
200000 TABLET, FILM COATED in 1 DRUM (0110-4479-71)
nui
N0000190857
unii
ISP4442I3Y
spl_set_id
7052c055-fedf-453b-86bc-01f5465eb157
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rdf-schema#range
https://w3id.org/def/predibionto#has_drug_105333
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect39062
owl#annotatedSource
t324792
owl#someValuesFrom
t3326781